Literature DB >> 26271830

Evaluation of hyaluronic acid-based combination adjuvant containing monophosphoryl lipid A and aluminum salt for hepatitis B vaccine.

Se-hee Moon1, Eui-Cheol Shin2, Young-Woock Noh1, Yong Taik Lim3.   

Abstract

Here, monophosphoryl lipid A (MPLA) and aluminum salt (Alum) were introduced into a hyaluronic acid (HA)-based combination vaccine adjuvant for hepatitis B vaccine (HBV). Although Alum is a well-known hepatitis B vaccine adjuvant that induces an enhanced humoral immune response, it cannot induce the cellular immune responses. On the other hand, MPLA has been generally reported to promote IFN-γ production via antigen-specific CD4(+) T cells, but it is not water soluble as a result of its long hydrophobic alkyl chains. To this end, water insoluble MPLA could be solubilized in an aqueous solution with the help of HA, which contains many carboxyl and hydroxyl groups that can be used to attach to the hydroxyl head groups of MPLA via hydrogen bonds. Three groups of mice were treated with either hepatitis B surface antigen (HBsAg) alone, HBsAg_Alum complex, or HBsAg_Alum_MPLA/HA complex. The group immunized with the HBsAg_Alum_MPLA/HA complex exhibited a high increase in cellular immune response as well as in humoral immune response relative to the other two groups. The antibody, cytokine and T cell levels were most elevated in the group of mice immunized with HBsAg_Alum_MPLA/HA complex, even at a 1μg/mice dose, and the magnitude was still maintained even after 8 weeks. Specifically, the antibody value was 120 times larger in mice vaccinated with HBsAg_Alum_MPLA/HA complex than in mice vaccinated with HBsAg_Alum complex designed similar to commercially available hepatitis B vaccine, Engerix B. The cytokine and T cell proliferation levels were 2 times and 6 times larger in mice adjuvanted with HBsAg_Alum_MPLA/HA complex than in those vaccinated with HBsAg_Alum. The results therefore indicate that incorporating MPLA and Alum with HA can be a potent strategy to increase both the magnitude and the persistence of HBsAg-specific immune responses to protect hosts against hepatitis B virus infection.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Adjuvant; Alum; Hepatitis B vaccine; Hyaluronic acid; MPLA

Mesh:

Substances:

Year:  2015        PMID: 26271830     DOI: 10.1016/j.vaccine.2015.08.006

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  9 in total

Review 1.  Developments in Vaccine Adjuvants.

Authors:  Farrhana Ziana Firdaus; Mariusz Skwarczynski; Istvan Toth
Journal:  Methods Mol Biol       Date:  2022

Review 2.  Hyaluronic acid association with bacterial, fungal and viral infections: Can hyaluronic acid be used as an antimicrobial polymer for biomedical and pharmaceutical applications?

Authors:  Fernanda Zamboni; Chun Kwok Wong; Maurice N Collins
Journal:  Bioact Mater       Date:  2022-05-02

3.  Potentiation of human papilloma vaccine candidate using naloxone/alum mixture as an adjuvant: increasing immunogenicity of HPV-16E7d vaccine.

Authors:  Mahsa Yasaghi; Mehdi Mahdavi
Journal:  Iran J Basic Med Sci       Date:  2016-09       Impact factor: 2.699

4.  A Pre-Clinical Safety Evaluation of SBP (HBsAg-Binding Protein) Adjuvant for Hepatitis B Vaccine.

Authors:  Jingbo Wang; Caixia Su; Rui Liu; Baoxiu Liu; Inam Ullah Khan; Jun Xie; Naishuo Zhu
Journal:  PLoS One       Date:  2017-01-19       Impact factor: 3.240

5.  Rational Design of Zika Virus Subunit Vaccine with Enhanced Efficacy.

Authors:  Wanbo Tai; Jiawei Chen; Yusen Zhou; Fang Li; Lanying Du; Guangyu Zhao; Qibin Geng; Lei He; Yuehong Chen
Journal:  J Virol       Date:  2019-08-13       Impact factor: 5.103

6.  Hyaluronan is a natural and effective immunological adjuvant for protein-based vaccines.

Authors:  Anna Dalla Pietà; Debora Carpanese; Antonella Grigoletto; Anna Tosi; Silvia Dalla Santa; Gabriel Kristian Pedersen; Dennis Christensen; Laura Meléndez-Alafort; Vito Barbieri; Paola De Benedictis; Gianfranco Pasut; Isabella Monia Montagner; Antonio Rosato
Journal:  Cell Mol Immunol       Date:  2021-03-24       Impact factor: 11.530

7.  Staphylococcus aureus derived hyaluronic acid and bacillus Calmette-Guérin purified proteins as immune enhancers to rabies vaccine and related immuno-histopathological alterations.

Authors:  Rania Ibrahim Shebl; Mohamed E Amer; Tamer M M Abuamara; Emadeldin R Matar; Hassan Fathy Ahmed; Tamer Albasyoni Gomah; Laila E El Moselhy; Mohammed Abu-Elghait; Aly Fahmy Mohamed
Journal:  Clin Exp Vaccine Res       Date:  2021-09-30

8.  The efficacy of a 2,4-diaminoquinazoline compound as an intranasal vaccine adjuvant to protect against influenza A virus infection in vivo.

Authors:  Kyungseob Noh; Eun Ju Jeong; Timothy An; Jin Soo Shin; Hyejin Kim; Soo Bong Han; Meehyein Kim
Journal:  J Microbiol       Date:  2022-04-18       Impact factor: 2.902

Review 9.  Hepatitis Vaccines.

Authors:  Sina Ogholikhan; Kathleen B Schwarz
Journal:  Vaccines (Basel)       Date:  2016-03-11
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.